The closing price of Ginkgo Bioworks Holdings Inc. (NYSE: DNA) was $1.96 for the day, down -4.85% from the previous closing price of $2.06. In other words, the price has decreased by -$0.1000 from its previous closing price. On the day, 16702736 shares were traded. DNA stock price reached its highest trading level at $2.0700 during the session, while it also had its lowest trading level at $1.9300.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
Ratios:
Our analysis of DNA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 11.70 and its Current Ratio is at 11.70. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.04.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Berenberg on November 29, 2022, initiated with a Buy rating and assigned the stock a target price of $6.
On October 04, 2022, Morgan Stanley started tracking the stock assigning a Equal-Weight rating and target price of $5.
BofA Securities Downgraded its Neutral to Underperform on May 18, 2022, while the target price for the stock was maintained at $3.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Feb 02 when Kelly Jason R sold 100,000 shares for $2.17 per share. The transaction valued at 216,790 led to the insider holds 13,889,486 shares of the business.
Canton Barry sold 37,650 shares of DNA for $81,618 on Feb 02. The 10% Owner now owns 14,701,248 shares after completing the transaction at $2.17 per share. On Feb 02, another insider, Shetty Reshma P., who serves as the insider of the company, sold 37,650 shares for $2.17 each. As a result, the insider received 81,618 and left with 14,701,248 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 6.04 while its Price-to-Book (P/B) ratio in mrq is 2.23.
Stock Price History:
Over the past 52 weeks, DNA has reached a high of $6.31, while it has fallen to a 52-week low of $1.45. The 50-Day Moving Average of the stock is 1.7864, while the 200-Day Moving Average is calculated to be 2.6065.
Shares Statistics:
DNA traded an average of 23.44M shares per day over the past three months and 19.78M shares per day over the past ten days. A total of 1.63B shares are outstanding, with a floating share count of 573.64M. Insiders hold about 5.40% of the company’s shares, while institutions hold 88.00% stake in the company. Shares short for DNA as of Oct 13, 2022 were 156.3M with a Short Ratio of 125.51M, compared to 187.61M on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 8.33% and a Short% of Float of 20.84%.
Earnings Estimates
The firm’s stock currently is rated by 5 analysts. On average, analysts expect EPS of -$0.3 for the current quarter, with a high estimate of -$0.06 and a low estimate of -$0.41, while EPS last year was -$0.06. The consensus estimate for the next quarter is -$0.2, with high estimates of -$0.05 and low estimates of -$0.34.
Analysts are recommending an EPS of between -$0.88 and -$1.45 for the fiscal current year, implying an average EPS of -$1.28. EPS for the following year is -$0.32, with 6 analysts recommending between -$0.07 and -$0.66.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 6 analysts. It ranges from a high estimate of $70.6M to a low estimate of $55M. As of the current estimate, Ginkgo Bioworks Holdings Inc.’s year-ago sales were $45.75M, an estimated increase of 31.90% from the year-ago figure. For the next quarter, 6 analysts are estimating revenue of $70.31M, a decrease of -52.70% less than the figure of $31.90% in the same quarter last year. There is a high estimate of $80.2M for the next quarter, whereas the lowest estimate is $66M.
A total of 8 analysts have provided revenue estimates for DNA’s current fiscal year. The highest revenue estimate was $463.8M, while the lowest revenue estimate was $382.99M, resulting in an average revenue estimate of $435.34M. In the same quarter a year ago, actual revenue was $313.84M, up 38.70% from the average estimate. Based on 8 analysts’ estimates, the company’s revenue will be $389.81M in the next fiscal year. The high estimate is $452.5M and the low estimate is $326.07M. The average revenue growth estimate for next year is down -10.50% from the average revenue estimate for this year.
